Ignite Creation Date:
2024-05-06 @ 9:00 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02875002
Status:
WITHDRAWN
Last Update Posted:
2017-12-22
First Post:
2016-08-17
Brief Title:
Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
Phase 1 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas
Status:
WITHDRAWN
Status Verified Date:
2017-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase 1 multicenter open-label study is designed to find the RP2D of volasertib a PLK1 inhibitor and belinostat an HDAC inhibitor when given in combination to patients with relapsed or refractory B-cell or T-cell lymphoma A standard 33 dose-escalation design will be employed with study enrollment beginning at dose level 1
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None